Skip to content

Intermittent Bolus Doses of Phenylephrine, Norepinephrine and Ephedrine for the Management of Spinal Induced Hypotension in Preeclamptic Patients

A Comparative Study of Intermittent Bolus Doses of Phenylephrine, Norepinephrine and Ephedrine for the Management of Spinal Induced Hypotension in Preeclamptic Patients

Status
Completed
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT07795710
Enrollment
150
Registered
2026-08-31
Start date
2024-01-30
Completion date
2024-01-30
Last updated
2026-08-31

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Ephedrine, Norepinephrine

Keywords

preeclamptic patients, spinal induced hypotension, norepinephrine, ephedrine

Brief summary

intermittent bolus doses of phenylephrine, norepinephrine and ephedrine for the management of spinal induced hypotension in preeclamptic patients

Detailed description

A Comparative study of intermittent bolus doses of phenylephrine, norepinephrine and ephedrine for the management of spinal induced hypotension in preeclamptic patients

Interventions

DRUGGroup 1 (P)

receive bolus dose of phenyelepherine 75 ug

DRUGGroup 2( N)

Group 2( N) will receive bolus dose of noradrenaline 4 ug

DRUGGroup 3( E)

Group 3( E) will receive bolus dose ephedrine 4 mg

Sponsors

Minia University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
DOUBLE (Caregiver, Outcomes Assessor)

Eligibility

Sex/Gender
FEMALE
Age
20 Years to 40 Years
Healthy volunteers
No

Inclusion criteria

* Preeclamptic pregnant female * ASA II and III * singleton or twin pregnancies will be scheduled for caesarean delivery * diagnosis of preeclampsia as a new onset of hypertension and proteinuria.

Exclusion criteria

* chronic hypertension, labor or failed trial of labor, * body mass index ≥40 kg/m2 , * resting heart rate \<60 bpm, eclampsia, * known fetal anomalies, contraindications to spinal anesthesia, abruption placentae, and cord prolapas.

Design outcomes

Primary

MeasureTime frame
Heart rate changesevery 3 minutes till 40 minutes

Secondary

MeasureTime frame
Systolic blood pressureevery 3 minutes till 40 minutes

Countries

Egypt

Contacts

PRINCIPAL_INVESTIGATORAli Ali, Assistant lecturer

Assistant lecturer

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Sep 1, 2026